(2018) 7:e34408
Not sure where to begin
Last updated: May 2026 to reflect discontinuation of Farxiga PAP for new patients on May 1, 2026.
1, 2025, or on the plan sponsor's 2025 renewal date
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, may induce a specific microbial footprint that differs from pure GLP-1 agonism, as GIP signaling independently participates in lipid handling and mucosal immune regulation, potentially modifying the nutrient-delivery profile to the gut ( Overall, differences between studies likely reflect heterogeneity in patient populations, diet, baseline microbiota, and treatment duration
Realistic expectations: GHK-Cu is a real, well-studied peptide with genuine effects but it isnt a miracle compound, and individual response varies